Indeed, the therapeutic scope for upregulation of autophagy by mTOR inhibitors extends beyond Huntington's disease, as CCI-779 treatment also demonstrated protective effects in a mouse model of spinocerebellar type 3 [70]. This evidence concerns the gene MTOR and juvenile Huntington disease.